SCHEMBL22043585

SCHEMBL22043585

N#Cc1ccc2c(c1)CO[C@@H]2c1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 3/20 0.40
TRPM5 Q9NZQ8 2/20 0.37
TRPM4 Q8TD43 1/20 0.37
DRD3 P35462 5/20 0.37
SLC6A4 P31645 4/20 0.37
SLC6A2 P23975 2/20 0.37
HTR2C P28335 2/20 0.37
ADRA1A P35348 2/20 0.37
HRH1 P35367 2/20 0.37
OPRM1 P35372 2/20 0.37
HTR2B P41595 2/20 0.37
KCNH2 Q12809 2/20 0.37
NPC1 O15118 1/20 0.37
SLC22A1 O15245 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CHRM2 P08172 1/20 0.37
HTR1A P08908 1/20 0.37
CHRM1 P11229 1/20 0.37
DRD1 P21728 1/20 0.37
ACHE P22303 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14199799 1.00 FADS1 (0.40) FADS1TRPM5TRPM4DRD3SLC6A4
SCHEMBL1686 1.00 FADS1 (0.40) FADS1TRPM5TRPM4DRD3SLC6A4
Oxalic Acid SCHEMBL15154934 0.92 LMNA (0.42) FADS1TRPM5TRPM4SLC6A4HTR7
SCHEMBL16312591 0.86 FADS1 (0.39) FADS1TRPM5TRPM4DRD3SLC6A4
SCHEMBL2812487 0.82 KMT2A (0.45) SLC6A4ALDH1A1BLMLMNA
SCHEMBL6096441 0.78 SLC6A2 (0.49) SLC6A4SLC6A2NPC1ACHESLC6A3
SCHEMBL1777 0.78 KDM1A (0.35) SLC6A4HTR7
SCHEMBL4622856 0.74 SLC5A2 (0.40) SLC6A4SLC6A2SLC6A3
SCHEMBL5936386 0.74 MEN1 (0.38) ALDH1A1SMN1; SMN2KDM4EMAPT
SCHEMBL6655779 0.74 NR3C1 (0.33) SLC6A4SLC6A2SLC6A3CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3659672-A1 COMBINED USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND HEMATOPOIETIC GROWTH FACTORS FOR TREATING HEMATOPOIETIC DISEASES Institut Gustave Roussy (FR) 2020-06-03 EP disclosed